

Foreign Direct Investment in Latin America and the Caribbean



Thank you for your interest in this ECLAC publication



Please register if you would like to receive information on our editorial products and activities. When you register, you may specify your particular areas of interest and you will gain access to our products in other formats.

Register



www.cepal.org/en/publications



www.instagram.com/publicacionesdelacepal





www.facebook.com/publicacionesdelacepal



www.issuu.com/publicacionescepal/stacks





www.cepal.org/es/publicaciones/apps



Foreign Direct Investment in Latin America and the Caribbean





José Manuel Salazar-Xirinachs

Executive Secretary

Raúl García-Buchaca

Deputy Executive Secretary for Management and Programme Analysis

Mario Castillo

Officer in Charge, Division of Production, Productivity and Management

Sally Shaw

Chief, Documents and Publications Division

The 2022 version of *Foreign Direct Investment in Latin America and the Caribbean* is the most recent edition of an annual series produced by the Unit on Investment and Corporate Strategies of the Division of Production, Productivity and Management of the Economic Commission for Latin America and the Caribbean (ECLAC). This year's edition was prepared by Leandro Cabello, Álvaro Calderón, Filipe Da Silva, Andrea Laplane, Stephania Mageste, Georgina Núñez and Nunzia Saporito, under the coordination of Cecilia Plottier. The databases were prepared by Leandro Cabello.

Comments and suggestions were received from Mario Cimoli, Mario Castillo, Martín Abeles, Olga Lucía Acosta, Jennifer Alvarado, Hugo Beteta, Miguel Cosmelli, Nicolo Gligo, Camila Gramkow, Sebastián Herreros, Jorge Mario Martínez, Carlos Mussi, Carolina Rocha, Giovanni Stumpo and Helvia Velloso.

The document was also prepared with inputs from the project "Inclusive and sustainable smart cities in the framework of the 2030 Agenda for Sustainable Development in Latin America and the Caribbean", implemented by ECLAC together with Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) and financed by the Federal Ministry of Economic Cooperation and Development (BMZ) of Germany.

Thanks are due to the government authorities and executives of companies consulted, for their inputs for the preparation of this document. Any comments or suggestions concerning the contents of this document should be addressed to Cecilia Plottier (maria.plottier@cepal.org). The boundaries and names shown on the maps included in this publication do not imply official acceptance or endorsement by the United Nations.

United Nations publication

ISBN: 978-92-1-122090-2 (print) ISBN: 978-92-1-005582-6 (pdf)

ISBN: 978-92-1-358322-7 (ePub) Sales No.: E.22.II.G.3

LC/PUB.2022/12-P Distribution: G

Copyright © United Nations, 2022

All rights reserved

Printed at United Nations, Santiago S.22-00561

Explanatory notes:

- Three dots (...) indicate that data are not available or are not separately reported.
- A dash (-) indicates that the amount is nil or negligible.
- A full stop (.) is used to indicate decimals.
- The word "dollars" refers to United States dollars, unless otherwise specified.
- A slash (/) between years (e.g. 2013/2014) indicates a 12-month period falling between the two years.
- Figures and percentages in tables may not always add up to the corresponding total because of rounding.

This publication should be cited as: Economic Commission for Latin America and the Caribbean (ECLAC), Foreign Direct Investment in Latin America and the Caribbean, 2022 (LC/PUB.2022/12-P), Santiago, 2022.

Applications for authorization to reproduce this work in whole or in part should be sent to the Economic Commission for Latin America and the Caribbean (ECLAC), Documents and Publications Division, publicaciones.cepal@un.org. Member States and their governmental institutions may reproduce this work without prior authorization, but are requested to mention the source and to inform ECLAC of such reproduction.

Executive summary			7	
Cha	pt	er I		
			of investment in Latin America and the Caribbean	
			ecovery strained by the international context	
-	3.	For	eign direct investment has not returned to its pre-pandemic level in the region	24
		1.	Foreign direct investment in 2021 was up 40.7% on the year before	
		2.	Investment in services recovered most quickly	28
		3.	The United States and the European Union: leading investors in the region	35
		4.	New investment announcements did not revive in 2021	37
		5.	Impact investments: new tools for financing sustainable projects in the region	39
(Ĵ.	Lat	in American investment abroad has reached pre-pandemic levels	42
[D. Conclusions		48	
1	Ξ.	Ana	alysis by country: all subregions received more foreign direct investment	51
		1.	The recovery of FDI in Brazil is explained by investment in services	53
		2.	South America: Chile, Peru and Uruguay were the countries showing the largest changes	55
		3.	Mexico sustained growth in FDI inflows	61
		4.	FDI inflows recovered in all the countries of Central America	63
		5.	The Caribbean: the Dominican Republic and Guyana consolidated their position	
			as largest FDI recipients	66
-	Bib	liog	raphy	71
1	٩nr	nex	I.A1	77
Cha	pt	er II		
For	eig	n di	irect investment in the region's pharmaceutical industry	89
ı	ntr	odu	ction	91
,	۵.	An	industry that is based on innovation, strictly regulated and constantly changing	91
		1.	Pre-production	93
		2.	Production	96
		3.	Post-production	100
-	В.	Inte	ernationalization has been linked to access to technologies and markets	100
		1.	Large United States and European firms lead the globalized marketplace	100
		2.	Mega mergers and large acquisitions have strengthened companies' international position	103
		3.	In Latin America and the Caribbean, FDI is concentrated in production and marketing	110
(Ĵ.	Latin America and the Caribbean: opportunities to strengthen capacity		
		in t	he pharmaceutical sector	
		1.	A strategic industry with an expanding market	
		2.	Exports weakened and the region was the main destination	
		3.	The need to define strategies in a changing world	123
		4.	The potential contribution of FDI to the development of the industry	124
		5.	Investment promotion agencies in Colombia, Costa Rica and Uruguay have prioritized the pharmaceutical sector	127
I	D.	Opp	portunities for the region and conclusions	129
I	Bib	liog	raphy	133
Cha	pt	er II	I	
The	er	ner	ging electric vehicle industry: opportunities for Latin America	137
	ction			
1	۵.	The	progress of electromobility: an emerging market with great potential?	140
		1.	Light electric vehicles are rapidly gaining market share	140
		2.	Electromobility also reaches heavy-duty vehicle segments	147

B.	Pot	ential for electric bus production in Latin America	155
	1.	The advance of electromobility in Latin American public transport	155
	2.	Conventional bus production capacity: a starting point for accelerating the electromobility transition	157
	3.	Brazil: epicentre of the first steps towards electric bus production	160
C.	Pol	icy recommendations and conclusions	168
	1.	Progress with public-public and public-private interconnections	166
	2.	Promoting mechanisms to plan and structure demand	167
	3.	Accelerating the replacement of bus fleets	168
	4.	Supporting the creation and consolidation of electric bus manufacturing capacities	168
	5.	Promoting investment in R&D	169
	6.	Additional measures	169
Bi	bliog	raphy	170
ECLA	C re	cent publications	175
Table	S		
Table	1.1	Global foreign direct investment inflows, rates of change and distribution by region, 2010–2021	19
Table	1.2	Latin America and the Caribbean: inward foreign direct investment, by recipient country and subregion, 2005–2009, 2010–2014 and 2015–2021	27
Table	1.3	Latin America and the Caribbean: 20 largest cross-border mergers and acquisitions, 2021	33
Table	1.4	Latin America and the Caribbean (selected countries): outward foreign direct investment, 2010–2014 and 2015–2021	42
Table	1.5	Largest cross-border mergers and acquisitions by Latin American and Caribbean firms, 2021	45
Table	I.A1.	3	77
Table		2008–2021	78
Table		by country of origin, 2007–2021	80
Table		by component, 2007–2021	83
Table		by country, 2001, 2005 and 2012–2021	86
Table		by country, 2003–2021	
Table		Key actors in the pharmaceutical value chain	
Table Table		Largest global pharmaceutical companies by revenue, 2021	
Table	11.4	2013—2021 Latin America and the Caribbean: top 10 cross-border mergers and acquisitions in the pharmaceutical sector, 2005—2021	
Table	III.1	Latin America: electric vehicle sales, selected countries, 2020–2021	
Table	III.2	National and subnational governments with official targets towards 100% zero-emission bus fleets, March 2022	
Table	III.3	Electric buses in Europe: sales and share of total, by country, 2020–2021	
Table	III.4	Original equipment manufacturers of conventional bus chassis with operations in Latin America, 2022	159
Table	III.5	Comparison between conventional and electric bus subsystems	160
Figur	es		
Figure	e 1	Latin America and the Caribbean: inward foreign direct investment, 2010–2021	S
Figure		Global foreign direct investment inflows, 1990–2021	20
Figure	e I.2	Global foreign direct investment project announcements, by destination region, 2005–2009, 2010–2014, 2015–2019, 2020 and 2021	21
Figure	e 1.3	Global foreign direct investment project announcements, selected sectors, 2005–2021	22

Figure I.4	Global foreign direct investment project announcements in the semiconductor sector, by destination country, 2005–2021	23
Figure I.5	Latin America and the Caribbean: inward foreign direct investment, 2010–2021	
Figure I.6	Latin America and the Caribbean: inward foreign direct investment, by component, 2010–2021	
Figure I.7	Latin America and the Caribbean: cross-border capital inflows, by functional category, 2010–2021	
Figure I.8	Latin America and the Caribbean: balance-of-payments current account, by component, 2010–2021	
Figure I.9	Latin America and the Caribbean (14 countries): sectoral distribution of inward foreign direct investment, 2010–2021	29
Figure I.10	Latin America and the Caribbean: cross-border mergers and acquisitions targeting companies in the region, 2005–2021	32
Figure I.11	Latin America and the Caribbean (11 countries): distribution of foreign direct investment inflows, by origin, 2015–2021	35
Figure I.12	Latin America and the Caribbean: mergers and acquisitions, by purchaser's country of origin, 2010–2021	36
Figure I.13	Latin America and the Caribbean: foreign direct investment project announcements, by country of origin, 2010–2021	36
Figure I.14	Latin America and the Caribbean: foreign direct investment project announcements, 2005–2021	37
Figure I.15	Latin America and the Caribbean: foreign direct investment project announcements, by sector, 2021 and changes 2020–2021	38
Figure I.16	Latin America and the Caribbean: issuance of environmental, social and governance (ESG) bonds on international debt markets, by type of instrument, 2015 to April 2022	40
Figure I.17	Latin America and the Caribbean: environmental, social and governance (ESG) bond issuance on international debt markets, sectoral distribution, December 2014 to April 2022	41
Figure I.18	Latin America and the Caribbean: stocks of outward foreign direct investment, 2010–2021	43
Figure I.19	Cross-border mergers and acquisitions by Latin American and Caribbean firms, 2005–2021	44
Figure I.20	Foreign direct investment project announcements by Latin American and Caribbean firms, 2003–2021	46
Figure I.21	Foreign direct investment project announcements by Latin American and Caribbean firms, by sector, 2020 and 2021	47
Figure II.1	Pharmaceutical companies with active R&D projects, by country or region, 2020	95
Figure II.2	Biotechnology and pharmaceutical patents, by region, 2020	95
Figure II.3	New chemical or biological entities developed, by region of origin, from 1998–2020	96
Figure II.4	Origin of active pharmaceutical ingredients in the European Union and United States, 2020	99
Figure II.5	Worldwide drug sales, 2001–2021	101
Figure II.6	Internationalization indices of pharmaceutical companies in the UNCTAD transnational ranking, 2020	. 102
Figure II.7	Transnational pharmaceutical company sales in Latin America, 2017–2020	103
Figure II.8	Cross-border mergers and acquisitions and FDI project announcements in the global pharmaceutical sector, 2003–2021	.106
Figure II.9	Global cross-border mergers and acquisitions with target companies in the pharmaceutical industry, by target region, 2013—2021	. 107
Figure II.10	Global FDI project announcements in the pharmaceutical industry, by region of destination, 2003–2021	. 108
Figure II.11	Global FDI project announcements in the pharmaceutical industry, by value chain subsegment and destination region, 2003–2021	. 109
Figure II.12	Brazil and Mexico: FDI inflows in the pharmaceutical industry, 2006–2021	110
Figure II.13	Latin America and the Caribbean: cross-border mergers and acquisitions and FDI project announcements in the pharmaceutical industry, 2005–2021	. 112
Figure II.14	Latin America and the Caribbean: cross-border mergers and acquisitions, by country and region of destination or country of origin, 2005–2021	. 113

Figure II.15	FDI project announcements in the pharmaceutical industry, by value chain segment, 2003—2021	115
Figure II.16	Latin America and the Caribbean: FDI project announcements, by country of destination and region of origin, 2003–2021	116
Figure II.17	Latin America (7 countries): apparent consumption in the pharmaceutical industry, annual average from 2018—2019	119
Figure II.18	Latin America (7 countries): gross value added in the pharmaceutical industry, annual average, 2016–2019	120
Figure II.19	Latin America (4 countries): share of domestic market sales of pharmaceutical products, by company ownership, 2020	120
Figure II.20	Latin America (11 countries): number of pharmaceutical establishments authorized to export to the United States and the European Union, 2022	121
Figure II.21	Latin America and the Caribbean: trade in pharmaceutical products, by main category, 2008–2020	122
Figure II.22	Latin America and the Caribbean: distribution of trade in pharmaceutical products, by category and country, 2020	123
Figure II.23	Patents expiring worldwide, by drug type, 2020–2026	130
Figure III.1	Global sales and market share of light electric vehicles, 2016–2021	142
Figure III.2	Sales of new light vehicles, by vehicle type and selected countries and regions, 2021–2035	142
Figure III.3	Electric buses: sales and total fleet shares, by selected countries and regions, 2015–2021	148
Figure III.4	Global exports of public transport vehicles, by type, 2017–2021	151
Figure III.5	Global trade in electric buses, 2017–2021	152
Figure III.6	Latin America: electric buses in circulation, by model and country, April 2022	156
Figure III.7	Latin America: electric buses in circulation, by manufacturer, April 2022	156
Figure III.8	Latin America: production of conventional buses, by country, 2011–2021 or most recent year available	158
Boxes		
Box I.1	Hydrocarbon investment and the quest for net zero	30
Box I.2	A taxonomy of sustainable investment	41
Box II.1	The use of patents in the pharmaceutical industry: a controversial reality	94
Box II.2	Stages of the regulatory process	97
Box II.3	The Agreement on Trade-Related Aspects of Intellectual Property Rights	104
Box II.4	Brazil: expansion and internationalization strategies of domestic pharmaceutical companies	114
Box II.5	Announcements of investments in the non-traditional medicine sector	117
Box II.6	The pharmaceutical industry in Mexico	126
Box II.7	Investing in R&D capacity-building: the Republic of Korea	132

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_32054



